期刊文献+

坎地沙坦酯自微乳软胶囊的制备和溶出度评价 被引量:1

Study on preparation and dissolution of candesartan cilexetile self-microemulsifying soft capsules
下载PDF
导出
摘要 目的研制坎地沙坦酯自微乳软胶囊,并对其溶出度进行评价。方法制备坎地沙坦酯自微乳软胶囊,并按药典方法考察自微乳软胶囊与普通胶囊在三种不同溶出介质(水、0.1mol/L盐酸和pH6.8的缓冲溶液)中的溶出度。结果坎地沙坦酯自微乳释药系统处方为乙酸乙酯:聚氧乙烯氢化蓖麻油RH40:聚乙二醇400为9∶14∶7。坎地沙坦酯自微乳受溶出介质的影响小,且溶出速率高于普通胶囊。结论自微乳软胶囊能显著提高坎地沙坦酯的体外溶出。 Objective To prepare candesartan cilexetile self-microemulsifying soft capsules and evaluate its dissolution. Methods The candesartan cilexetile self-microemulsifying soft capsules were prepared. The dissolution of soft capsules and common capsule were investigated in three different dissolution medium (water, 0.1 mol/L hydrochloric acid and pH 6.8 buffer solution) in accordance with the pharmacopoeia. Results The self-microemulsifying drug delivery system was composed of acetic ether (as oil): RH40 (as emulsifier): PEG400 (as co-emulsifier) = 9 ∶ 14 ∶ 7. The dissolution release of soft capsule was not influenced by the different dissolution medium. And the drug release rate of soft capsule was faster than the common capsule. Conclusion The dissolution of candesartan cilexetile soft capsule was remarkably improved.
出处 《中国现代药物应用》 2011年第20期1-2,共2页 Chinese Journal of Modern Drug Application
基金 武汉市科技局攻关项目(项目编号:200960323126)
关键词 坎地沙坦酯 自微乳 软胶囊 溶出度 Candesartan cilexetile Self-emulsifying Capsule Dissolution
  • 相关文献

参考文献5

  • 1刘桂芹.坎地沙坦酯的临床应用及其研究进展[J].现代中西医结合杂志,2009,18(36):4592-4594. 被引量:10
  • 2何颖娜,尚京川.抗高血压新药——坎地沙坦酯[J].重庆医学,2004,33(12):1896-1898. 被引量:14
  • 3Pouton CW. Lipid formulation for oral administration of drugs: Non-emulsifying, self-emulsifying and " self-mien)emulsifying" dru~ delivery systems. Eur J Pharm Sci. 2000.11 ( 2 ) :93 -98.
  • 4葛翠明 王东凯 顾艳丽 等.白微乳药物传递系统的研究进展[J].中国药剂学杂志,2003,.
  • 5Kawakami K,Yoshikawa T,Moroto Y, et al. Microemulsion formu- lation for enhanced absorption of poorly soluble drugs 1 : Prescrip- tion desigT1. J Controlled Release,2002,81 (1-2) :65-74.

二级参考文献24

  • 1蔡德山.浅谈沙坦类抗高血压新药市场[J].中国制药信息,2007,23(4):29-32. 被引量:2
  • 2Johnston CL. Angiotensin receptor antagonists: focus on losartan [J]. Lancet,2000,346(8987):1403-1407.
  • 3Gleiter CH,Jagle C, Gresser U, et al. Candesartan Cardiovasc[J ] Drug Rev,2004,22(4):263-284.
  • 4Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan [J ]. Clinical Pharmacokinetics, 2002,41 ( 1 ) : 7 - 17.
  • 5Oparil S, Levine JH, Zuschke CA, et al. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators[J]. Am J Cardiol, 1999,84(3) :289 - 293.
  • 6Me Kelvie RS,Rouleau J, Latini R, et al. Comparison of candesartun, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigatotrs[J ]. Circulation, 1999,100(10) : 1056 - 1064.
  • 7Mitrovic V, Willenbrock R, Miric M, et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure[J]. Am Heart J ,2003,145(3) :E14.
  • 8Baguet JP,Barone-Rochette G, Neuder Y. Candesartan cilexetil in the treatment of chronic heart failure[J]. Vasc Health Risk Manag,2009,5(1):257-264.
  • 9Mitrovic V, Appel KF, Proskynitopoulos N, et al. Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice[J ]. Clin Res Cardiol,2009,18.
  • 10Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-lreoeptor antagonism reverses endothelial dysfunction in atherosclerosis[J]. Circulation,2000,101 (20) :2349 -2354.

共引文献21

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部